An H3K4me3 reader, BAP18 as an adaptor of COMPASS-like core subunits co-activates ERα action and associates with the sensitivity of antiestrogen in breast cancer

Abstract Estrogen receptor alpha (ERα) signaling pathway is essential for ERα-positive breast cancer progression and endocrine therapy resistance. Bromodomain PHD Finger Transcription Factor (BPTF) associated protein of 18kDa (BAP18) has been recognized as a crucial H3K4me3 reader. However, the whole genomic occupation of BAP18 and its biological function in breast cancer is still elusive. Here, we found that higher expression of BAP18 in ERα-positive breast cancer is positively correlated with poor prognosis. ChIP-seq analysis further demonstrated that the half estrogen response elements (EREs) and the CCCTC binding factor (CTCF) binding sites are the significant enrichment sites found in estrogen-induced BAP18 binding sites. Also, we provide the evidence to demonstrate that BAP18 as a novel co-activator of ERα is required for the recruitment of COMPASS-like core subunits to the cis-regulatory element of ERα target genes in breast cancer cells. BAP18 is recruited to the promoter regions of estrogen-induced genes, accompanied with the enrichment of the lysine 4-trimethylated histone H3 tail (H3K4me3) in the presence of E2. Furthermore, BAP18 promotes cell growth and associates the sensitivity of antiestrogen in ERα-positive breast cancer. Our data suggest that BAP18 facilitates the association between ERα and COMPASS-like core subunits, which might be an essential epigenetic therapeutic target for breast cancer.

[1]  R. Schiff,et al.  Enhancer reprogramming driven by high-order assemblies of transcription factors promotes phenotypic plasticity and breast cancer endocrine resistance , 2020, Nature Cell Biology.

[2]  A. Tackett,et al.  Delivery of phosphatidylethanolamine blunts stress in hepatoma cells exposed to elevated palmitate by targeting the endoplasmic reticulum , 2020, Cell Death Discovery.

[3]  M. Elchebly,et al.  BORIS/CTCFL promotes a switch from a proliferative towards an invasive phenotype in melanoma cells , 2020, Cell death discovery.

[4]  R. Schiff,et al.  FOXA1 upregulation promotes enhancer and transcriptional reprogramming in endocrine-resistant breast cancer , 2019, Proceedings of the National Academy of Sciences.

[5]  T. Huang,et al.  A Non-canonical Role of YAP/TEAD Is Required for Activation of Estrogen-Regulated Enhancers in Breast Cancer. , 2019, Molecular cell.

[6]  Bandana Sharma,et al.  BORIS promotes chromatin regulatory interactions in treatment-resistant cancer cells , 2019, Nature.

[7]  M. Rubin,et al.  CHD1 Loss Alters AR Binding at Lineage-Specific Enhancers and Modulates Distinct Transcriptional Programs to Drive Prostate Tumorigenesis. , 2019, Cancer cell.

[8]  M. Elchebly,et al.  BORIS/CTCFL promotes a switch from a proliferative towards an invasive phenotype in melanoma cells , 2019, Cell Death Discovery.

[9]  A. Regev,et al.  Acquired HER2 mutations in ER+ metastatic breast cancer confer resistance to estrogen receptor–directed therapies , 2018, Nature Genetics.

[10]  J. Lee,et al.  HER2 Overexpression Triggers an IL1α Proinflammatory Circuit to Drive Tumorigenesis and Promote Chemotherapy Resistance. , 2018, Cancer research.

[11]  E. Winer,et al.  Drug Resistance in HER2-Positive Breast Cancer Brain Metastases: Blame the Barrier or the Brain? , 2018, Clinical Cancer Research.

[12]  Jiayuh Lin,et al.  Inhibition of IL-6/STAT3 signaling in human cancer cells using Evista. , 2017, Biochemical and biophysical research communications.

[13]  Aamir Ali,et al.  MLL/WDR5 Complex Regulates Kif2A Localization to Ensure Chromosome Congression and Proper Spindle Assembly during Mitosis. , 2017, Developmental cell.

[14]  I. Mills,et al.  CTCF modulates Estrogen Receptor function through specific chromatin and nuclear matrix interactions , 2016, Nucleic acids research.

[15]  Liu Cao,et al.  BAP18 coactivates androgen receptor action and promotes prostate cancer progression , 2016, Nucleic acids research.

[16]  P. V. van Diest,et al.  Recruitment of the Mammalian Histone-modifying EMSY Complex to Target Genes Is Regulated by ZNF131* , 2016, The Journal of Biological Chemistry.

[17]  C. A. Toro,et al.  Epigenetic regulation of puberty via Zinc finger protein-mediated transcriptional repression , 2015, Nature Communications.

[18]  F. Tashiro,et al.  SGF29 and Sry pathway in hepatocarcinogenesis. , 2015, World journal of biological chemistry.

[19]  G. Poda,et al.  Pharmacological targeting of the Wdr5-MLL interaction in C/EBPα N-terminal leukemia , 2015, Nature chemical biology.

[20]  Shiuan Chen,et al.  Cross-talk between ER and HER2 regulates c-MYC-mediated glutamine metabolism in aromatase inhibitor resistant breast cancer cells , 2015, The Journal of Steroid Biochemistry and Molecular Biology.

[21]  Liu Cao,et al.  MDC1 functionally identified as an androgen receptor co-activator participates in suppression of prostate cancer , 2015, Nucleic acids research.

[22]  J. Thornton,et al.  Molecular basis for DPY-30 association to COMPASS-like and NURF complexes. , 2014, Structure.

[23]  T. Urano,et al.  The N-terminus and Tudor domains of Sgf29 are important for its heterochromatin boundary formation function. , 2014, Journal of biochemistry.

[24]  Howard Y. Chang,et al.  Essential role of lncRNA binding for WDR5 maintenance of active chromatin and embryonic stem cell pluripotency , 2014, eLife.

[25]  David Chen,et al.  ESR1 ligand binding domain mutations in hormone-resistant breast cancer , 2013, Nature Genetics.

[26]  Javed Siddiqui,et al.  Activating ESR1 mutations in hormone-resistant metastatic breast cancer , 2013, Nature Genetics.

[27]  K. Mizuguchi,et al.  Targeting BIG3–PHB2 interaction to overcome tamoxifen resistance in breast cancer cells , 2013, Nature Communications.

[28]  Xun Lan,et al.  Amplification of distant estrogen response elements deregulates target genes associated with tamoxifen resistance in breast cancer. , 2013, Cancer cell.

[29]  M. Vermeulen,et al.  A Dual Role for SAGA-Associated Factor 29 (SGF29) in ER Stress Survival by Coordination of Both Histone H3 Acetylation and Histone H3 Lysine-4 Trimethylation , 2013, PloS one.

[30]  D. Yee,et al.  Fulvestrant regulates epidermal growth factor (EGF) family ligands to activate EGF receptor (EGFR) signaling in breast cancer cells , 2013, Breast Cancer Research and Treatment.

[31]  R. Janknecht,et al.  KDM4/JMJD2 histone demethylases: epigenetic regulators in cancer cells. , 2013, Cancer research.

[32]  D. Odom,et al.  CTCF and Cohesin: Linking Gene Regulatory Elements with Their Targets , 2013, Cell.

[33]  M. Jouvenot,et al.  Epigenetic regulation of estrogen signaling in breast cancer , 2013, Epigenetics.

[34]  Michelle Grayson.  Breast cancer , 2012, Nature.

[35]  M. Willingham,et al.  Resistance to thyroid hormone is modulated in vivo by the nuclear receptor corepressor (NCOR1) , 2011, Proceedings of the National Academy of Sciences.

[36]  S. Fuqua,et al.  Farnesoid X receptor inhibits tamoxifen-resistant MCF-7 breast cancer cell growth through downregulation of HER2 expression , 2011, Oncogene.

[37]  P. Grant,et al.  Sgf29 binds histone H3K4me2/3 and is required for SAGA complex recruitment and histone H3 acetylation , 2011, The EMBO journal.

[38]  H. Korswagen,et al.  Caenorhabditis elegans chromatin-associated proteins SET-2 and ASH-2 are differentially required for histone H3 Lys 4 methylation in embryos and adult germ cells , 2011, Proceedings of the National Academy of Sciences.

[39]  Jonathan M. Monk,et al.  Wdr5 Mediates Self-Renewal and Reprogramming via the Embryonic Stem Cell Core Transcriptional Network , 2011, Cell.

[40]  Yu Shyr,et al.  A Gene Expression Signature from Human Breast Cancer Cells with Acquired Hormone Independence Identifies MYC as a Mediator of Antiestrogen Resistance , 2011, Clinical Cancer Research.

[41]  T. Tsukiyama,et al.  SnapShot: Chromatin Remodeling: ISWI , 2011, Cell.

[42]  A. Singer,et al.  Chromatin remodeling complex NURF regulates thymocyte maturation. , 2011, Genes & development.

[43]  A. Hyman,et al.  Quantitative Interaction Proteomics and Genome-wide Profiling of Epigenetic Histone Marks and Their Readers , 2010, Cell.

[44]  Johan Hartman,et al.  FOXM1 is a transcriptional target of ERα and has a critical role in breast cancer endocrine sensitivity and resistance , 2010, Oncogene.

[45]  Robert L. Sutherland,et al.  Biological determinants of endocrine resistance in breast cancer , 2009, Nature Reviews Cancer.

[46]  M. Demay,et al.  Wdr5 Is Essential for Osteoblast Differentiation* , 2008, Journal of Biological Chemistry.

[47]  Sean D. Taverna,et al.  How chromatin-binding modules interpret histone modifications: lessons from professional pocket pickers , 2007, Nature Structural &Molecular Biology.

[48]  T. Kouzarides.  Chromatin Modifications and Their Function , 2007, Cell.

[49]  C. Allis,et al.  Methylation of lysine 4 on histone H3: intricacy of writing and reading a single epigenetic mark. , 2007, Molecular cell.

[50]  M. Vigneron,et al.  CTCF Interacts with and Recruits the Largest Subunit of RNA Polymerase II to CTCF Target Sites Genome-Wide , 2007, Molecular and Cellular Biology.

[51]  Myles A Brown,et al.  Estrogen receptor target gene: an evolving concept. , 2006, Molecular endocrinology.

[52]  Thomas A Milne,et al.  Regulation of MLL1 H3K4 methyltransferase activity by its core components , 2006, Nature Structural &Molecular Biology.

[53]  Thomas A. Milne,et al.  A PHD finger of NURF couples histone H3 lysine 4 trimethylation with chromatin remodelling , 2006, Nature.

[54]  Yi-jun Zhu,et al.  Identification of the MLL2 Complex as a Coactivator for Estrogen Receptor α* , 2006, Journal of Biological Chemistry.

[55]  Ali Shilatifard,et al.  Chromatin modifications by methylation and ubiquitination: implications in the regulation of gene expression. , 2006, Annual review of biochemistry.

[56]  Xing Wang Deng,et al.  Structural basis for the specific recognition of methylated histone H3 lysine 4 by the WD-40 protein WDR5. , 2006, Molecular cell.

[57]  S. Khorasanizadeh,et al.  Double chromodomains cooperate to recognize the methylated histone H3 tail , 2005, Nature.

[58]  W. Herr,et al.  Leukemia Proto-Oncoprotein MLL Forms a SET1-Like Histone Methyltransferase Complex with Menin To Regulate Hox Gene Expression , 2004, Molecular and Cellular Biology.

[59]  C. Peterson,et al.  The SANT domain: a unique histone-tail-binding module? , 2004, Nature Reviews Molecular Cell Biology.

[60]  Carlos S. Moreno,et al.  MTA3, a Mi-2/NuRD Complex Subunit, Regulates an Invasive Growth Pathway in Breast Cancer , 2003, Cell.

[61]  Thomas A Milne,et al.  MLL targets SET domain methyltransferase activity to Hox gene promoters. , 2002, Molecular cell.

[62]  D. McDonnell,et al.  Identification of a negative regulatory surface within estrogen receptor alpha provides evidence in support of a role for corepressors in regulating cellular responses to agonists and antagonists. , 2002, Molecular endocrinology.

[63]  Stuart L. Schreiber,et al.  Methylation of histone H3 Lys 4 in coding regions of active genes , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[64]  Donald P. McDonnell,et al.  Connections and Regulation of the Human Estrogen Receptor , 2002, Science.

[65]  L. Xia,et al.  Sp1 and ETS family transcription factors regulate the mouse Mta2 gene expression. , 2001, Gene.

[66]  C K Osborne,et al.  Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[67]  R. Bernards,et al.  CDK-Independent Activation of Estrogen Receptor by Cyclin D1 , 1997, Cell.

[68]  K. Bomsztyk,et al.  Protocol for the fast chromatin immunoprecipitation (ChIP) method , 2006, Nature Protocols.

[69]  H. Iwase,et al.  [Breast cancer]. , 2006, Nihon rinsho. Japanese journal of clinical medicine.

[70]  Tony Kouzarides,et al.  Histone H3 lysine 4 methylation patterns in higher eukaryotic genes , 2004, Nature Cell Biology.

[71]  V. Jordan,et al.  “Studies on the estrogen receptor in breast cancer” — 20 years as a target for the treatment and prevention of cancer , 2004, Breast Cancer Research and Treatment.